A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia
Phase of Trial: Phase II
Latest Information Update: 14 Feb 2018
At a glance
- Drugs Obinutuzumab (Primary) ; Vemurafenib (Primary)
- Indications Hairy cell leukaemia
- Focus Therapeutic Use
- 09 Feb 2018 Status changed from not yet recruiting to recruiting.
- 01 Feb 2018 Planned initiation date changed from 1 Jan 2018 to 1 Feb 2018.
- 29 Jan 2018 New trial record